Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.38 |
| ▸ | GRM5 | P41594 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | FPR1 | P21462 | 1/20 | 0.35 |
| ▸ | FPR3 | P25089 | 1/20 | 0.35 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107742 | 0.81 | GRM5 (0.38) | FFAR1GRM5ALDH1A1TSHRGAA | |
| SCHEMBL2109417 | 0.81 | ALDH1A1 (0.37) | GRM5ALDH1A1TSHRGAAPRSS1 | |
| SCHEMBL2108693 | 0.81 | KCNH2 (0.39) | FFAR1GRM5ALDH1A1TSHRGAA | |
| SCHEMBL2108729 | 0.78 | TSHR (0.39) | FFAR1GRM5ALDH1A1TSHRCHRM2 | |
| SCHEMBL2109624 | 0.76 | KDM4E (0.47) | FFAR1GRM5ALDH1A1TSHRGAA | |
| SCHEMBL2110165 | 0.73 | CA12 (0.40) | FFAR1GRM5ALDH1A1TSHRGAA | |
| SCHEMBL28273863 | 0.72 | TSHR (0.59) | FFAR1GRM5ALDH1A1TSHRCHRM2 | |
| SCHEMBL3644208 | 0.72 | TSHR (0.62) | FFAR1GRM5ALDH1A1TSHRCHRM2 | |
| SCHEMBL30666154 | 0.72 | TSHR (0.62) | FFAR1GRM5ALDH1A1TSHRCHRM2 | |
| SCHEMBL1252899 | 0.71 | ERN1 (0.47) | FFAR1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | COSTANZO MICHAEL J (US) | 2012-06-28 | — | — | US | claimed |
| US-8158792-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | claimed |
| EP-2224803-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2010-09-08 | — | — | EP | claimed |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2009-06-25 | — | — | US | claimed |
| WO-2009067202-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-28 | — | — | WO | claimed |
| US-8536189-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | COSTANZO MICHAEL J (US) | 2012-06-28 | — | — | US | disclosed |
| US-8158792-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| EP-2224803-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2010-09-08 | — | — | EP | disclosed |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2009-06-25 | — | — | US | disclosed |
| WO-2009067202-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | FFAR1 1335/4885GRM5 1591/4885ALDH1A1 450/4885 |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | TPSAB1, TPSB2, TPSD1 | FFAR1 1335/4885GRM5 1591/4885ALDH1A1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.